LBA1: LATIFY: No survival benefit with ceralasertib plus durvalumab versus docetaxel in patients with previously treated advanced NSCLC

WCLC 2025

Lung, Respiratory and Thoracic Cancer

EMPOWER-Lung 3: Cemiplimab plus chemotherapy provide sustained survival benefits in patients with advanced NSCLC

Genitourinary Cancer

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

Lancet Oncol

Gupta S, Loriot Y, Van der Heijden MS, Bedke J, Valderrama BP, Kikuchi E, Fléchon A, Petrylak D, De Santis M, Galsky MD, Lee JL, Swami U, Sridhar SS, De Giorgi U, Wright P, Shih V, Lu YT, Guan X, Dillon R, Shetty A, Moreno BH, Beaumont JL, Purnajo I, McManus S, Powles T

doi: 10.1016/S1470-2045(25)00158-5

Lung, Respiratory and Thoracic Cancer

Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1

J Thorac Oncol

Peters S, Regan MM, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Brahmer JR, Penrod JR, Li J, Tracy L, Yuan Y, Bushong J, Lee A, Eccles LJ, Ray S, Ramalingam SS

doi: 10.1016/j.jtho.2025.05.019

Lung, Respiratory and Thoracic Cancer

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis

Lung Cancer

Hayashi H, Cho BC, Kim YJ, Lee SH, Danchaivijitr P, Alip A, Xiong H, How SH, Chang GC, Yang JC, Yamanaka Y, Nahit Şendur MA, Prabhash K, Azuma K, Akawung A, Fennema E, Tang X, Shah S, Sethi S, Lu S

doi: 10.1016/j.lungcan.2026.109305

Leukemia

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model

Leukemia

Venditti A, Hou JZ, Fenaux P, Jonas BA, Vrhovac R, Montesinos P, Garcia JS, Rizzieri D, Thirman MJ, Zhang M, Potluri J, Miller C, Dhalla M, Pullarkat V

doi: 10.1038/s41375-025-02730-3

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

MARIPOSA Study: Frontline amivantamab plus lazertinib reduces acquired resistance versus osimertinib in patients with NSCLC harboring common EGFR mutations*

Lung, Respiratory and Thoracic Cancer

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

Lung Cancer

Wheatley-Price P, Navani V, Pabani A, Routy B, Snow S, Denault MH, Kim Y, Syed I, Devost N, Hui D, Qadeer RA, Arora P, Velummailum R, Springford A, McKibbon C, Ho C

doi: 10.1016/j.lungcan.2025.108583

WCLC 2025

Lung, Respiratory and Thoracic Cancer

CheckMate 816: Neoadjuvant nivolumab plus chemotherapy provides long-term OS benefit in patients with early-stage NSCLC

ESMO 2025

Breast Cancer

Related content

EMPOWER-Lung 3: Cemiplimab plus chemotherapy provide sustained survival benefits in patients with advanced NSCLC

Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study

Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1

Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model

MARIPOSA Study: Frontline amivantamab plus lazertinib reduces acquired resistance versus osimertinib in patients with NSCLC harboring common EGFR mutations*

Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study

CheckMate 816: Neoadjuvant nivolumab plus chemotherapy provides long-term OS benefit in patients with early-stage NSCLC

monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer